We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

36 hedge funds and large institutions have $64.6M invested in Biolase, Inc. in 2014 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

53% more capital invested

Capital invested by funds: $42.2M → $64.6M (+$22.4M)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 35 → 36 (+1)

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
6
Increased
10
Reduced
1
Closed
5
Calls
$139K
Puts
–
Net Calls
+$139K
Net Calls Change
+$172K

Top Buyers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
+$7.1M
2
OIM
Oracle Investment Management
Connecticut
+$5.16M
3
EAM
Eagle Asset Management
Florida
+$2M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$156K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$156K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$487K
2
Group One Trading
Group One Trading
Illinois
-$206K
3
PP
Paloma Partners
Connecticut
-$34K
4
Bank of America
Bank of America
North Carolina
-$31.3K
5
PCM
Perkins Capital Management
Minnesota
-$31.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$84K – – –
Millennium Management
27
Millennium Management
New York
$80K – – –
Stifel Financial
28
Stifel Financial
Missouri
$69K – – –
EIM
29
Essex Investment Management
Massachusetts
$63K – – –
State Street
30
State Street
Massachusetts
$51K – – –
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$46K – – –
Citadel Advisors
32
Citadel Advisors
Florida
$44K +$31.3K +1 New
Deutsche Bank
33
Deutsche Bank
Germany
$38K – – –
BA
34
BlackRock Advisors
Delaware
$29K – – –
RCM
35
Rotella Capital Management
Washington
$27K +$31.3K +1 New
FANJ
36
Financial Architects (New Jersey)
New Jersey
$26K +$31.3K +1 New
BIM
37
BlackRock Investment Management
Delaware
$14K – – –
UBS Group
38
UBS Group
Switzerland
$8K – – –
Bank of America
39
Bank of America
North Carolina
$7K -$31.3K -1 Closed
WA
40
Waverly Advisors
Alabama
$7K – – –
MAM
41
Meeder Asset Management
Ohio
$5K – – –
Creative Planning
42
Creative Planning
Kansas
$2K – – –
LTFS
43
Ladenburg Thalmann Financial Services
Florida
$2K – – –
TRCT
44
Tower Research Capital (TRC)
New York
$1K – – –
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4 – – –
Wellington Management Group
46
Wellington Management Group
Massachusetts
– -$487K -16 Closed
Group One Trading
47
Group One Trading
Illinois
– -$206K -7 Closed
PP
48
Paloma Partners
Connecticut
– -$34K -1 Closed
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
– -$25K -1 Closed
Barclays
50
Barclays
United Kingdom
– -$3K – –
1
2
3

BIOL Hedge Fund Activity: Q4 2014 in Review

36 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2014, worth a combined $64.6M — up 53% from $42.2M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIOL positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 1 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $7.1M. The largest seller was Wellington Management Group, exiting entirely with an estimated $487K sold.

  • 36 institutional investors held Biolase, Inc. (BIOL) as of Q4 2014, up from 35 in Q3 2014.
  • Funds reported $64.6M of Biolase, Inc. stock for Q4 2014, up 53% quarter-over-quarter.
  • 6 funds opened new Biolase, Inc. positions in Q4 2014 and 5 closed out, a net change of +1 holder.
  • The largest Biolase, Inc. buyer in Q4 2014 was Camber Capital Management, an estimated $7.1M added.
  • The largest Biolase, Inc. seller in Q4 2014 was Wellington Management Group, an estimated $487K sold.

Based on aggregated 13F filings for Q4 2014.